Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

Iván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, Matthew Evans, Matthew Smith, Linea Melchior, Werner Reiltin, Michael Bennett, Veronica Pennati, Francesca Castiglione, Karl Friedrich Bürrig, Ulrike Cooper, Barbara Dockhorn-Dworniczak, Christiana Rossenbach, Claudia M. Luna-Aguirre, Hugo A. Barrera-Saldaña, José C. Machado, José L. Costa, Rinat Yacobi, Hilla Tabibian-KeissarSimonetta Buglioni, Livia Ronchetti, Lotte Douglas-Berger, Hendrikus J. Dubbink, Mohammed Alorini, Jean Christophe Sabourin, Federico Rojo

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.

Original languageEnglish
Pages (from-to)664-676
Number of pages13
JournalJournal of Molecular Diagnostics
Volume20
Issue number5
DOIs
StatePublished - Sep 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 American Society for Investigative Pathology and the Association for Molecular Pathology

Funding

Supported by each clinical center; work at Vitagénesis, SA de CV (Monterrey, Mexico), was supported by the Fund for Technology Innovation Pharmacogenetics and Precision Medicine grant CONACyT 260826; work at Fundación Jiménez Díaz University Hospital was supported by Institute of Health Carlos III (CIBERONC grants PI15/00934 and PT17/0015/0006). Idylla NRAS-BRAF Mutation Test cartridges were provided by Biocartis.

FundersFunder number
Instituto de Salud Carlos IIIPI15/00934, PT17/0015/0006
Consejo Nacional de Ciencia y Tecnología260826

    Fingerprint

    Dive into the research topics of 'Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

    Cite this